Monoamine oxidase B
Also known as: MAO-B, MAOB
Mitochondrial enzyme that preferentially degrades dopamine. It is selectively inhibited by selegiline and rasagiline, used in Parkinson's disease.
Selective MAO-B inhibition at therapeutic doses has lower tyramine interaction risk, but combination with serotonergic drugs (SSRIs, pethidine) retains serotonin syndrome risk.
Substrates: dopamine, tyramine (to a lesser extent than MAO-A).
Inhibitors: selegiline, rasagiline.
Inducers: not applicable.
Avoid combining selegiline with pethidine (potentially fatal documented interaction) and with SSRIs.
DailyMed/FDA (NIH/NLM) — approved labels (selegiline); EMC-UK (MHRA) — SmPC
